Blinatumomab for the treatment of acute lymphoblastic leukemia: an update
| Autor: | Caitlin R. Rausch, Patrice Nasnas, Shilpa Paul, Elias Jabbour, Hagop M. Kantarjian |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty biology business.industry Health Policy Lymphoblastic Leukemia Negativity effect Minimal residual disease 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases 030220 oncology & carcinogenesis Internal medicine Relapsed refractory biology.protein medicine Pharmacology (medical) Blinatumomab Antibody business Pharmacology Toxicology and Pharmaceutics (miscellaneous) 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Expert Opinion on Orphan Drugs. 7:41-46 |
| ISSN: | 2167-8707 |
| DOI: | 10.1080/21678707.2019.1571408 |
| Popis: | Introduction: Blinatumomab is a first-in-class bispecific T-cell engager (BiTE) antibody that has demonstrated high response rates, including minimal or measurable residual disease (MRD) negativity... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|